Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: WU, WEN-SHUO, CHEN, YUH-MIN, TSAI, CHUN-MING, SHIH, JEN-FU, CHIU, CHAO-HUA, CHOU, KUN-TA, LAI, SHINN-LIANG, WU, CHIEH-HUNG, LUO, YUNG-HUNG, HUANG, CHU-YUN, LEE, YU-CHIN, PERNG, REURY-PERNG, WHANG-PENG, JACQUELINE
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2012
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3438713/
https://ncbi.nlm.nih.gov/pubmed/22969870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2011.383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados